Exelixis, Inc.
Key Metrics
Market Snapshot
About
Exelixis, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of new medicines for cancer treatment. The company's flagship product is CABOMETYX (cabozantinib), a kinase inhibitor approved for advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Exelixis has built a diverse pipeline of oncology compounds targeting various cancer types through both internal research and strategic partnerships. The company has collaborations with major pharmaceutical firms including Ipsen, Takeda, and Genentech to develop and commercialize its therapies globally.